solitomab
vanucizumab
gevokizumab
retifanlimab
abagovomab
tislelizumab
immunoglobulin E
sintilimab
antinucleosome
heterophile
antipolyvalent
antigenically
atezolizumab
heteroclitic
agonistic monoclonal antibody
antisynthetase
polyvalent
multiantigenic
guselkumab
polytypic
heterophilic
immunoglobin
brentuximab
immunosorbent
cytotoxic reaction
paratope
sonepcizumab
tucotuzumab
elotuzumab
allotope
immunoprobe
oportuzumab monatox
bivatuzumab
polyantibody
cross-reactivity
alacizumab
immunospecific
amlitelimab
microlymphocytotoxicity
antimonoclonal
immunorepressive
intetumumab
anti-nuclear factor
polyantigenic
crossreactive